Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
- Status
- UNKNOWN
- Phase
- N/A
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- NA
KRDI in Transplant-Eligible MM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- Status
- TERMINATED
- Phase
- PHASE2
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
- Status
- SUSPENDED
- Phase
- PHASE1
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Status
- TERMINATED
- Phase
- PHASE1
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- Status
- COMPLETED
- Phase
- PHASE4